| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6514531 | SANOFI AVENTIS US | Controlled-release dosage forms comprising zolpidem or a salt thereof |
Dec, 2019
(4 years ago) | |
|
US6514531 (Pediatric) | SANOFI AVENTIS US | Controlled-release dosage forms comprising zolpidem or a salt thereof |
Jun, 2020
(3 years ago) | |
Ambien Cr is owned by Sanofi Aventis Us.
Ambien Cr contains Zolpidem Tartrate.
Ambien Cr has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Ambien Cr are:
- US6514531
- US6514531*PED
Ambien Cr was authorised for market use on 02 September, 2005.
Ambien Cr is available in tablet, extended release;oral dosage forms.
The generics of Ambien Cr are possible to be released after 01 June, 2020.
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 02 September, 2005
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of AMBIEN CR before it's drug patent expiration?
More Information on Dosage
AMBIEN CR family patents
